MLL
BBH icon

Moody Lynn & Lieberson’s VanEck Biotech ETF BBH Stock Holding History

Moody Lynn & Lieberson’s Portfolio BBH Stock Details BBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-39,040
Closed -$4.65M – 216
2017
Q1 		$4.65M Buy
+39,040
New +$4.57M 0.65% 53

Other funds holding BBH

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
MCM
Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
SFS
Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return
BRM
Boston Research & Management Manchester, Massachusetts $421M AUM 16.18% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
AL
Aspiriant LLC Los Angeles, California $3.51B AUM 13.98% 1-Year Est. Return

Moody Lynn & Lieberson's BBH Position: Q2 2017 in Review

Moody Lynn & Lieberson sold out of VanEck Biotech ETF (BBH) in Q2 2017, closing a stake of 39,040 shares — an estimated $4.65M sold.

Moody Lynn & Lieberson first reported a position in BBH in Q1 2017 and held it in 1 quarter. The position peaked at $4.65M in Q1 2017. 83 funds tracked by Wall St. Rank hold BBH as of Q2 2017.

  • Moody Lynn & Lieberson reported no remaining VanEck Biotech ETF position as of Q2 2017 after selling out during the quarter.
  • Moody Lynn & Lieberson sold 39,040 VanEck Biotech ETF shares in Q2 2017, an estimated $4.65M.
  • Moody Lynn & Lieberson first reported a position in VanEck Biotech ETF in Q1 2017 and held it in 1 quarter.
  • Moody Lynn & Lieberson's VanEck Biotech ETF position peaked at $4.65M in Q1 2017.
  • 83 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2017.

Based on Moody Lynn & Lieberson's 13F filing for Q2 2017, filed 26 Jul 2017.